BEGIN:VCALENDAR VERSION:2.0 PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.41.90// CALSCALE:GREGORIAN UID:33633736-3966-4539-a166-326362333736 BEGIN:VEVENT UID:e042368b5681e240cdce8d47cbd07def0a189972@swoogo.com DTSTAMP:20260905T025428Z DESCRIPTION:AstraZeneca (AZ) is a global\, research-driven biopharmaceutica l company committed to advancing science and improving patient outcomes. T his 60-minute breakout session will provide an evidence-based update on re cent developments across AZ’s Biopharmaceuticals and Oncology portfolios\, emphasizing clinical value\, unmet need\, and implications for evidence-b ased formulary\, utilization\, and access decisions in federal and related integrated care delivery systems. Part 1: Biopharmaceuticals Unit (Cardio renal Metabolism and Respiratory) We will review late-stage and emerging t herapies targeting key drivers of cardiovascular and respiratory disease b urden. In hypertension\, we will discuss an oral\, mechanism-based approac h designed to address persistent blood pressure elevation in patients on m ultidrug regimens\, with a focus on efficacy\, safety\, and potential impa ct on control rates\, monitoring\, and care pathways in integrated systems . In dyslipidemia\, we will examine an oral nonstatin strategy that has sh own clinically meaningful LDL C reductions as monotherapy and as an adjunc t to statins\, with attention to positioning in stepwise lipid lowering al gorithms\, adherence considerations\, and potential implications for popul ation-health management. In COPD\, we will highlight a biologically target ed therapy that modulates upstream epithelial and inflammatory signaling a ssociated with exacerbations\, exploring the potential to reduce acute car e utilization\, improve quality of life\, and inform pathway alignment and access decisions. Part 2: Oncology Business Unit AZ is advancing a compre hensive oncology strategy focused on delivering transformative therapies a cross multiple tumor types through scientific innovation and strategic col laboration. This part will highlight the company’s clinical development ap proach with emphasis on thoracic malignancies and near term studies\, incl uding an antibody drug conjugate platform in lung cancer designed to addre ss critical unmet needs through targeted delivery. Attendees will gain ins ight into the late stage pipeline\, recent data releases\, and opportuniti es for collaboration with federal accounts to enhance access to cutting ed ge therapies for veterans. The discussion will underscore the value of sus tained collaboration between AZ and federal accounts in driving innovation \, accelerating research\, and improving outcomes in oncology\, including operational considerations for pathway alignment\, diagnostics integration \, and care coordination. Across both parts\, presenters will integrate cl inical evidence to support transparent\, data driven decisions. Time will be reserved and the end of the presentation to answer questions in both th erapeutic areas. DTSTART:20260303T193000Z DTEND:20260303T203000Z LAST-MODIFIED:20260905T025428Z LOCATION: SEQUENCE:0 STATUS:CONFIRMED SUMMARY:Advancing Cardiorenal Metabolism\, Respiratory\, and Oncology Care Through Innovation and Collaboration to Improve Patient Outcomes: An Updat e from AstraZeneca TRANSP:OPAQUE X-ALT-DESC;FMTTYPE=text/html:

AstraZeneca (AZ) is a global\, research-dri ven biopharmaceutical company committed to advancing science and improving patient outcomes. This 60-minute breakout session will provide an evidenc e-based update on recent developments across AZ’s Biopharmaceuticals and O ncology portfolios\, emphasizing clinical value\, unmet need\, and implica tions for evidence-based formulary\, utilization\, and access decisions in federal and related integrated care delivery systems. Part 1: Biopharmace uticals Unit (Cardiorenal Metabolism and Respiratory) We will review late- stage and emerging therapies targeting key drivers of cardiovascular and r espiratory disease burden. In hypertension\, we will discuss an oral\, mec hanism-based approach designed to address persistent blood pressure elevat ion in patients on multidrug regimens\, with a focus on efficacy\, safety\ , and potential impact on control rates\, monitoring\, and care pathways i n integrated systems. In dyslipidemia\, we will examine an oral nonstatin strategy that has shown clinically meaningful LDL C reductions as monother apy and as an adjunct to statins\, with attention to positioning in stepwi se lipid lowering algorithms\, adherence considerations\, and potential im plications for population-health management. In COPD\, we will highlight a biologically targeted therapy that modulates upstream epithelial and infl ammatory signaling associated with exacerbations\, exploring the potential to reduce acute care utilization\, improve quality of life\, and inform p athway alignment and access decisions. Part 2: Oncology Business Unit AZ i s advancing a comprehensive oncology strategy focused on delivering transf ormative therapies across multiple tumor types through scientific innovati on and strategic collaboration. This part will highlight the company’s cli nical development approach with emphasis on thoracic malignancies and near term studies\, including an antibody drug conjugate platform in lung canc er designed to address critical unmet needs through targeted delivery. Att endees will gain insight into the late stage pipeline\, recent data releas es\, and opportunities for collaboration with federal accounts to enhance access to cutting edge therapies for veterans. The discussion will undersc ore the value of sustained collaboration between AZ and federal accounts i n driving innovation\, accelerating research\, and improving outcomes in o ncology\, including operational considerations for pathway alignment\, dia gnostics integration\, and care coordination. Across both parts\, presente rs will integrate clinical evidence to support transparent\, data driven d ecisions. Time will be reserved and the end of the presentation to answer questions in both therapeutic areas.

BEGIN:VALARM UID:31633766-3664-4638-b339-666463616131 ACTION:DISPLAY DESCRIPTION:AstraZeneca (AZ) is a global\, research-driven biopharmaceutica l company committed to advancing science and improving patient outcomes. T his 60-minute breakout session will provide an evidence-based update on re cent developments across AZ’s Biopharmaceuticals and Oncology portfolios\, emphasizing clinical value\, unmet need\, and implications for evidence-b ased formulary\, utilization\, and access decisions in federal and related integrated care delivery systems. Part 1: Biopharmaceuticals Unit (Cardio renal Metabolism and Respiratory) We will review late-stage and emerging t herapies targeting key drivers of cardiovascular and respiratory disease b urden. In hypertension\, we will discuss an oral\, mechanism-based approac h designed to address persistent blood pressure elevation in patients on m ultidrug regimens\, with a focus on efficacy\, safety\, and potential impa ct on control rates\, monitoring\, and care pathways in integrated systems . In dyslipidemia\, we will examine an oral nonstatin strategy that has sh own clinically meaningful LDL C reductions as monotherapy and as an adjunc t to statins\, with attention to positioning in stepwise lipid lowering al gorithms\, adherence considerations\, and potential implications for popul ation-health management. In COPD\, we will highlight a biologically target ed therapy that modulates upstream epithelial and inflammatory signaling a ssociated with exacerbations\, exploring the potential to reduce acute car e utilization\, improve quality of life\, and inform pathway alignment and access decisions. Part 2: Oncology Business Unit AZ is advancing a compre hensive oncology strategy focused on delivering transformative therapies a cross multiple tumor types through scientific innovation and strategic col laboration. This part will highlight the company’s clinical development ap proach with emphasis on thoracic malignancies and near term studies\, incl uding an antibody drug conjugate platform in lung cancer designed to addre ss critical unmet needs through targeted delivery. Attendees will gain ins ight into the late stage pipeline\, recent data releases\, and opportuniti es for collaboration with federal accounts to enhance access to cutting ed ge therapies for veterans. The discussion will underscore the value of sus tained collaboration between AZ and federal accounts in driving innovation \, accelerating research\, and improving outcomes in oncology\, including operational considerations for pathway alignment\, diagnostics integration \, and care coordination. Across both parts\, presenters will integrate cl inical evidence to support transparent\, data driven decisions. Time will be reserved and the end of the presentation to answer questions in both th erapeutic areas. TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR